SCHEMBL888071

SCHEMBL888071

CC(c1ccccc1[N+](=O)[O-])[C@]1(n2ccc(N)nc2=O)C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
THRB P10828 1/20 0.37
MTOR P42345 1/20 0.37
MDM2 Q00987 1/20 0.37
NCOA1 Q15788 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
PDE3A Q14432 3/20 0.36
SLC29A1 Q99808 2/20 0.36
PDE4D Q08499 1/20 0.36
CACNA1F O60840 2/20 0.31
ALB P02768 2/20 0.31
MAPT P10636 2/20 0.31
CACNA1D Q01668 2/20 0.31
CACNA1S Q13698 2/20 0.31
CACNA1C Q13936 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL888028 0.83 LMNA (0.38) LMNATHRBMTORMDM2NCOA1
SCHEMBL888100 0.80 SLC28A1 (0.42) SLC29A1
SCHEMBL888172 0.78 SLC29A1 (0.37) LMNATHRBMTORMDM2NCOA1
Phosphoric Acid SCHEMBL888082 0.78 SLC28A1 (0.40) SLC29A1
SCHEMBL7005263 0.76 PDE3A (0.37) LMNATHRBMTORMDM2NCOA1
Phosphoric Acid SCHEMBL1514933 0.76 SLC29A1 (0.35) LMNATHRBMTORMDM2NCOA1
SCHEMBL1763155 0.73 PDE3A (0.42) LMNATHRBMTORMDM2NCOA1
SCHEMBL51650 0.72 PDE3A (0.46) LMNATHRBMTORMDM2NCOA1
SCHEMBL992472 0.72 PDE3A (0.46) LMNATHRBMTORMDM2NCOA1
SCHEMBL27544566 0.72 PDE3A (0.46) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125856-B1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN INC (US) 2016-09-14 EP disclosed
US-8361727-B2 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2013-01-29 US disclosed
US-20110287427-A1 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2011-11-24 US disclosed
US-7964352-B2 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2011-06-21 US disclosed
US-7897737-B2 Polymorphic identification; fluorescent dyes LASERGEN, INC. (US) 2011-03-01 US disclosed
US-20090081686-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2009-03-26 US disclosed
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing AGILENT TECHNOLOGIES, INC. 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing UNG, DCLRE1B, NT5C3B LMNA 131/4885THRB 3911/4885MTOR 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.